Patches and method for the transdermal delivery of a therapeutically effective amount of iron
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61N-001/30
A61K-009/00
A61K-009/70
A61K-031/295
A61K-033/26
A61K-038/18
A61N-001/04
출원번호
US-0459183
(2009-06-25)
등록번호
US-8996104
(2015-03-31)
발명자
/ 주소
Berenson, Ronald J.
출원인 / 주소
FE3 Medical, Inc.
대리인 / 주소
Alston & Bird LLP
인용정보
피인용 횟수 :
1인용 특허 :
45
초록▼
Embodiments of the invention provide patches for the transdermal delivery of iron-containing compositions to an individual suffering from an iron deficiency. Many embodiments provide an iontophoretic patch for the transdermal delivery of a therapeutically effective amount of iron. The patch comprise
Embodiments of the invention provide patches for the transdermal delivery of iron-containing compositions to an individual suffering from an iron deficiency. Many embodiments provide an iontophoretic patch for the transdermal delivery of a therapeutically effective amount of iron. The patch comprises an electrode and a reservoir containing a composition comprising ionic iron for the delivery of the therapeutically effective amount of iron. Various embodiments provide methods of using embodiments of the iontophoretic patch for delivering a therapeutically effective amount of iron to an individual suffering from one more forms of iron deficiency including iron deficiency anemia. Such methods can be used for treating and/or preventing the iron deficiency. The amount of delivered iron can be adjusted depending upon various treatment parameters such as patient weight and type and amount of iron deficiency.
대표청구항▼
1. A method for the transdermal iontophoretic delivery of a composition comprising ionic iron to an individual in need thereof, comprising: contacting the individual with a patch comprising an active electrode and a reservoir including a composition comprising ionic iron, the reservoir and compositi
1. A method for the transdermal iontophoretic delivery of a composition comprising ionic iron to an individual in need thereof, comprising: contacting the individual with a patch comprising an active electrode and a reservoir including a composition comprising ionic iron, the reservoir and composition being separate from the electrode; andapplying current from the active electrode to the reservoir to cause transdermal iontophoretic delivery of a therapeutically effective amount of ionic iron from the reservoir to the individual, wherein the composition does not include heme iron or heme iron polypeptide. 2. The method of claim 1, wherein the ionic iron is in the form of one or more ferrous salts. 3. The method of claim 2, wherein the one or more ferrous salts are selected from the group consisting of: ferrous gluconate, ferrous chloride, ferrous sulfate, and ferrous fumarate. 4. The method of claim 1, wherein the composition comprises at least one agent selected from the group consisting of: a vitamin supplement, erythropoietin, and an erythropoietin stimulating agent. 5. The method of claim 4, wherein the vitamin supplement is selected from the group consisting of thiamine, riboflavin, niacin, pantothenic acid, pyroxidine, biotin, folic acid, and cobalamin. 6. The method of claim 1, wherein the therapeutically effective amount of delivered ionic iron is in a range from about 1 mg to about 50 mg of elemental iron. 7. The method of claim 1, wherein the therapeutically effective amount of delivered ionic iron is in a range from about 1 mg to about 40 mg of elemental iron. 8. The method of claim 1, wherein the therapeutically effective amount of delivered ionic iron is in a range from about 1 mg to about 30 mg of elemental iron. 9. The method of claim 1, further comprising adjusting the therapeutically effective amount of ionic delivered iron to the individual based on a treatment parameter. 10. The method of claim 9, wherein the treatment parameter is a patient characteristic, patient weight, type of iron deficiency being treated or selected therapeutic outcome. 11. The method of claim 1, wherein the ionic iron composition is delivered substantially continuously. 12. The method of claim 1, wherein the ionic iron composition is delivered over a period of about one day to about one month. 13. The method of claim 1, wherein the ionic iron composition is delivered over a period of about one day to about one week. 14. The method of claim 13, wherein the ionic iron composition is delivered over a period of about one day to about three days. 15. The method of claim 14, wherein the ionic iron composition is delivered over a period of about one day. 16. The method of claim 15, wherein the therapeutically effective amount of delivered ionic iron is in a range from about 1 mg to about 50 mg of elemental iron. 17. The method of claim 1, further comprising: delivering sufficient iron to prevent and/or treat an iron deficiency in an individual. 18. The method of claim 17, further comprising administering a parental therapeutically effective amount of iron. 19. The method of claim 18, wherein the parental administration is done prior to transdermal delivery. 20. The method of claim 18, wherein the parental administration is intravenous or subcutaneous. 21. The method of claim 18, wherein at least one of the parental administration and the transdermal delivery are adjusted relative to the other. 22. The method of claim 21, wherein the adjustment is in at least one of a rate or amount of iron delivery. 23. The method of claim 17, further comprising administering an oral therapeutically effective amount of iron. 24. The method of claim 23, wherein the oral administration is done prior to the transdermal delivery. 25. The method of claim 17, further comprising administering an intravenous bolus of iron to the individual prior transdermal delivery wherein the bolus contains about 500 mg to 1 gram of iron. 26. The method of claim 17, wherein the individual has an iron deficiency without anemia. 27. The method of claim 26, wherein the iron deficiency is being treated in order to prevent growth retardation, cognitive disabilities, and/or mental retardation. 28. The method of claim 26, wherein the iron deficiency, is caused by chronic alcoholism; poor nutrition; decreased consumption of animal protein and absorbic acid; increased iron demands of pregnancy, infancy, or adolescence; malabsorption syndromes; and foods or drugs that reduce the gastrointestinal absorption of iron. 29. The method of claim 17, wherein the individual has an iron deficiency anemia. 30. The method of claim 29, wherein the individual has an iron deficiency characterized by microcytosis of red blood cells, a hemoglobin iron binding capacity of less than 20%, ferritin levels less than about 10 μg/L, or transferrin iron saturation levels less than 20%. 31. The method of claim 17, wherein the individual has a functional iron deficiency with ferritin levels less than 100 μg/L. 32. The method of claim 17, wherein the individual is selected from the group consisting of a child, infant, and neonate. 33. The method of claim 17, wherein the therapeutically effective amount of delivered ionic iron is in a range from about 0.5 mg to about 40 mg of elemental iron. 34. The method of claim 17, wherein the therapeutically effective amount of delivered ionic iron is in a range from about 0.5 mg to about 20 mg of elemental iron. 35. The method of claim 17, wherein the therapeutically effective amount of delivered ionic iron is adjusted based on an anthropomorphic parameter or an indicator of iron deficiency. 36. The method of claim 17, wherein the ionic iron composition is delivered over a period of about one day to about one week. 37. The method of claim 1, further comprising: creating a plurality of micro channels in the stratum corneum to enhance transdermal delivery of the ionic iron. 38. The method of claim 37, wherein the plurality of micro-channels are created mechanically. 39. The method of claim 38, wherein the plurality of micro-channels are created using a plurality of needles. 40. The method of claim 38, wherein the plurality of micro-channels are created using an electrical discharge on or into the skin. 41. The method of claim 40, wherein the discharge is created using a plurality of conductive microfilaments. 42. A method for the transdermal iontophoretic delivery of a composition comprising ionic iron to an individual in need thereof, the method comprising: contacting the individual with a patch comprising an active electrode and a reservoir including a pharmaceutical composition comprising ionic iron, wherein the composition is uniformly distributed within the reservoir, the reservoir and composition being separate from the electrode; andapplying current from the active electrode to the reservoir to cause transdermal iontophoretic delivery of a therapeutically effective amount of ionic iron from the reservoir to the individual wherein the composition does not include heme iron or heme iron polypeptide.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (45)
Yuzhakov Vadim Vladimirovich ; Sherman Faiz Feisal ; Owens Grover David ; Gartstein Vladimir, Apparatus and method for using an intracutaneous microneedle array.
Eppstein, Jonathan A.; Hatch, Michael R.; Papp, Joseph, Apparatus for microporation of biological membranes using thin film tissue interface devices, and method therefor.
Muller Daniel,FRX ; Perie Frederic,FRX ; Barbier Alain,FRX, Device for ionophoresis comprising at least a membrane electrode assembly, for the transcutaneous administration of active principles to a subject.
Jacobsen Stephen C. (274 S. 1220 East Salt Lake City UT 84102) Petelenz Tomasz J. (623 University Village UT 84108) Stephen Robert L. (2501 Kensington Ave. Salt Lake City UT 84108), Flow-through methods and apparatus for iontophoresis application of medicaments at a controlled pH.
Muller Daniel,FRX ; Barbier Alain,FRX ; Saunal Henry,FRX, Iontophoresis device for the transcutaneous delivery of an active principle such as an anionic oligosaccharide.
Haak Ronald P. (San Jose CA) Gyory J. Richard (San Jose CA) Theeuwes Felix (Los Altos CA) Myers Robert M. (Stanford CA), Iontophoretic delivery device and method of hydrating same.
Tamarkin,Dov; Mavor,Daniela; Nitzan,Zvi; Arbel,Giora; Harel,Nurit; Luski,Shalom; Gross,Yossi, Kit, device and method for controlled delivery of oxidizing agent into the skin.
Lerner, Eduard N., Method and device for enhanced delivery of a biologically active agent through the spinal spaces into the central nervous system of a mammal.
Miller,David J.; Higuchi,William I.; Li,Kevin; Flynn,Gordon L., Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent.
Dede Lszl (Budapest HUX) Dede ne Pl Mria (Budapest HUX) Bogdny Lszl (Budapest HUX) Bogdny ne Forgcs Olga (Budapest HUX), Protein and mineral water-containing cosmetic compositions.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.